Practice-Changing Results with Abiraterone plus Prednisone in Metastatic Hormone-Naïve Prostate Cancer

TON - November 2017, Vol 10, No 6 - Prostate Cancer
Meg Barbor, MPH

New Orleans, LA—For patients with metastatic hormone-naïve prostate cancer, practice-changing results from the LATITUDE clinical trial showed that the use of abiraterone plus low-dose prednisone in addition to androgen-deprivation therapy (ADT) delayed disease progression by an average of 18 months, and reduced the risk for death by 38%, when compared with ADT alone.

The study was presented at the 2017 American Society of Clinical Oncology Annual Meeting, and later discussed by Lorinda A. Coombs, PhD candidate, MSN, RN, FNP-BC, AOCNP, Assistant Clinical Professor, University of California San Francisco School of Nursing, at the 12th Annual New Orleans Summer Cancer Meeting.

The current standard of care for me­­t­astatic hormone-naïve prostate cancer is docetaxel plus ADT. However, older patients with prostate cancer “often have comorbidities, and those comorbidities contribute to a poor performance status, which is exacerbated by the use of docetaxel,” Ms Coombs said.

She went on to say that the incidence of metastatic prostate cancer continues to rise in the United States. Some experts have hypothesized that changes in the screening guidelines regarding routine prostate-specific antigen testing have resulted in patients with prostate cancer being diagnosed later in the course of their disease.

“I don’t think we have enough evidence to know that for certain, but it definitely suggests that our screening methods should come under scrutiny,” Ms Coombs said.

Prostate cancer growth is fueled by testosterone, and ADT prevents testicles from making testosterone. However, despite ADT, the adrenal glands and prostate cancer cells continue to make small amounts of androgen. Abir­aterone stops the production of testosterone by blocking an enzyme that converts other hormones to testosterone.

Increase in Overall Survival a “Home Run”

The double-blind, placebo-controlled phase 3 LATITUDE clinical trial enrolled 1199 men at 235 sites in 34 countries. Patients in the study were aged >18 years, with an Eastern Cooperative Oncology Group Performance Status score 0 to 2.

“Very functional patients were enrolled in this trial,” noted Ms Coombs. Patients were newly diagnosed (≤3 months) and had not previously received ADT.

All patients had at least 2 of 3 risk factors, including a Gleason score ≥8, ≥3 bony lesions, or measurable visceral me­t­astases (spread to other organs in certain areas of the body, such as the liver).

“This was not subtle disease,” she added.

Patients were randomized 1:1 to ADT plus abiraterone (1000 mg daily) and prednisone (5 mg daily), or to ADT plus dual placebos. Co-primary end points were overall survival (OS) and radiographic progression-free survival.

After a median follow-up of 30.4 months, patients in the abiraterone group showed significant improvements in OS. Median OS in the placebo group was 34.7 months, and was not reached in the abiraterone group.

“That’s what you call a home run in terms of a clinical trial,” she said. These findings led to a unanimous agreement to unblind the study and allow for crossover.

“Patients who received abiraterone lived longer, and that is always the gold standard of any randomized controlled trial. You want to see a real-time benefit, not a subtle one,” said Ms Coombs.

Abiraterone also delayed cancer progression by approximately 18 months, and median progression-free survival was 33 months in the group that received the drug, compared with 14.8 months in the placebo group.

“But nothing in life or in cancer therapy is free,” she added. Ninety-three percent of patients in both arms experienced some sort of treatment-related adverse event, but grade 3 or 4 adverse events were more prevalent in the abir­aterone group. Hypertension occurred in 37% of patients in the abiraterone group compared with 22% in the placebo group, and hypokalemia was observed in 20% and 4% of patients, respectively.

“In short, abiraterone plus prednisone increases OS, so we should be starting patients with metastatic hormone-naïve prostate cancer on this regimen. These significant results will influence practice,” asserted Ms Coombs.

However, it is important to monitor for grade ≥3 hypertension and hypokalemia in patients receiving this regimen.

Related Items
Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018
The Importance of Compassion: Perspective From a Lifelong Patient
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018
Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018
Improving Education for Nurse Practitioners Delivering Survivorship Care
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Survivorship
Maintaining Work and Productivity a Priority for Cancer Survivors
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Survivorship
Encourage Minority Patients with Ovarian Cancer to Participate in Clinical Trials
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Gynecologic Cancers
Updates on Immunotherapy in Advanced Melanoma
Meg Barbor, MPH
TOP - May 2018, Vol 11, No 1 published on May 1, 2018 in Melanoma, HOPA 2018 Highlights
Apalutamide and Enzalutamide Each Delays Prostate Cancer Metastasis by Approximately 2 Years
Phoebe Starr
TOP - May 2018, Vol 11, No 1 published on May 1, 2018 in Prostate Cancer
Understanding Immunotherapy Late Adverse Effects in Cancer Survivors
Meg Barbor, MPH
TOP - May 2018, Vol 11, No 1 published on May 1, 2018 in Adverse Effects
Targeting FMS-Like Tyrosine Kinase 3 in the Management of Patients with FLT3-Positive Acute Myeloid Leukemia
Meg Barbor, MPH
TOP - May 2018, Vol 11, No 1 published on May 1, 2018 in HOPA 2018 Highlights, Leukemia
Last modified: December 8, 2017